These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 30445420)
1. Bayesian estimation of a semiparametric recurrent event model with applications to the penetrance estimation of multiple primary cancers in Li-Fraumeni syndrome. Shin SJ; Li J; Ning J; Bojadzieva J; Strong LC; Wang W Biostatistics; 2020 Jul; 21(3):467-482. PubMed ID: 30445420 [TBL] [Abstract][Full Text] [Related]
2. Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective. Shin SJ; Dodd-Eaton EB; Gao F; Bojadzieva J; Chen J; Kong X; Amos CI; Ning J; Strong LC; Wang W Cancer Res; 2020 Jan; 80(2):347-353. PubMed ID: 31719099 [TBL] [Abstract][Full Text] [Related]
3. Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. Shin SJ; Dodd-Eaton EB; Peng G; Bojadzieva J; Chen J; Amos CI; Frone MN; Khincha PP; Mai PL; Savage SA; Ballinger ML; Thomas DM; Yuan Y; Strong LC; Wang W Cancer Res; 2020 Jan; 80(2):354-360. PubMed ID: 31719101 [TBL] [Abstract][Full Text] [Related]
4. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician. Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253 [TBL] [Abstract][Full Text] [Related]
5. Cancer Risks Associated With Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388 [TBL] [Abstract][Full Text] [Related]
6. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers. Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928 [TBL] [Abstract][Full Text] [Related]
7. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family. Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898 [TBL] [Abstract][Full Text] [Related]
8. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes. Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481 [TBL] [Abstract][Full Text] [Related]
9. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965 [TBL] [Abstract][Full Text] [Related]
10. Bayesian Semiparametric Estimation of Cancer-specific Age-at-onset Penetrance with Application to Li-Fraumeni Syndrome. Shin SJ; Yuan Y; Strong LC; Bojadzieva J; Wang W J Am Stat Assoc; 2019; 114(526):541-552. PubMed ID: 31485091 [TBL] [Abstract][Full Text] [Related]
11. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry. Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S; JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041 [TBL] [Abstract][Full Text] [Related]
12. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil. Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735 [TBL] [Abstract][Full Text] [Related]
13. Estimating Peng G; Bojadzieva J; Ballinger ML; Li J; Blackford AL; Mai PL; Savage SA; Thomas DM; Strong LC; Wang W Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):837-844. PubMed ID: 28137790 [No Abstract] [Full Text] [Related]
14. Next generation sequencing is informing phenotype: a TP53 example. O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937 [TBL] [Abstract][Full Text] [Related]
15. Hematologic malignancies and Li-Fraumeni syndrome. Swaminathan M; Bannon SA; Routbort M; Naqvi K; Kadia TM; Takahashi K; Alvarado Y; Ravandi-Kashani F; Patel KP; Champlin R; Kantarjian H; Strong L; DiNardo CD Cold Spring Harb Mol Case Stud; 2019 Feb; 5(1):. PubMed ID: 30709875 [TBL] [Abstract][Full Text] [Related]
16. The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome. Macaulay S; Goodyear QC; Kruger M; Chen W; Essop F; Krause A Fam Cancer; 2018 Oct; 17(4):607-613. PubMed ID: 29392648 [TBL] [Abstract][Full Text] [Related]
17. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289 [TBL] [Abstract][Full Text] [Related]
18. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation. Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190 [TBL] [Abstract][Full Text] [Related]
19. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. Valdez JM; Nichols KE; Kesserwan C Br J Haematol; 2017 Feb; 176(4):539-552. PubMed ID: 27984644 [TBL] [Abstract][Full Text] [Related]
20. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]